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Abstract Tremelimumab (CP 675206; CP-675; CP-675,206; CP-675206; Ticilimu-
mab) is a fully human IgG2 anitbody, which is directed against human cyto-
toxic T lymphocyte-associated antigen 4 (CTLA4). It is being developed by
Pfizer for the treatment of various cancers. It is currently in worldwide phase
III development for malignant melanoma, phase II development for colo-
rectal cancer, gastrointestinal cancer, gynecological cancer, and non-small
cell lung cancer in the US and other countries, and is also being investigated
for prostate, breast, and pancreatic cancer in various countries. This review
discusses the key development milestones and therapeutic trials of this drug.
1. Introduction
Tremelimumab (formerly ticilimumab) is a
fully human IgG2 monoclonal antibody, which
is directed against human cytotoxic T lympho-
cyte-associated antigen 4 (CTLA4), it is also
an interleukin-2 (IL-2) stimulant. The antibody
is being developed by Pfizer as an anticancer
agent, which was generated using XenoMouse
technology provided by Abgenix (now Amgen).
Tremelimumab is in clinical development for the
treatment of various cancers.
CTLA4 (CD152) is a cell surface receptor ex-
pressed on activatedT cells. Inmice, T cell-mediated
killing of tumors is enhanced by blocking the
binding to CTLA4 of its natural ligands, such as
B7.1 (CD80) and B7.2 (CD86), which are ex-
pressed on antigen-presenting cells.
1.1 Company Agreements
In January 2010, Pfizer and Debiopharm
Group entered into a co-development agreement
to conduct a phase III trial of tremelimumab
for the treatment of patients with unresectable,
stage IV melanoma. A biomarker will be used to
select patients considered likely to respond to
tremelimumab. Under the terms of the agree-
ment, Debiopharm will assume responsibility for
conducting the phase III trial of tremelimumab
and Pfizer will retain responsibility for worldwide
commercialization of the compound. Financial
terms of the agreement were not disclosed.[1]
In September 2004, Medarex and Pfizer signed
a strategic alliance, and exchanged non-exclusive
licenses to patents relating to antibodies to
CTLA4. Pursuant to this license agreement,
Medarex has the potential to receive milestone
and royalty payments based upon commercial
sales of any Pfizer anti-CTLA4 antibody prod-
uct, including tremelimumab.[2]
1.2 Key Development Milestones
A rollover protocol, phase II study
(NCT00378482) intended to provide access to
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tremelimumab for patients who have previously
received this drug in a clinical trial is taking place
in the US and UK. This open-label study will
enroll approximately 200 patients at locations in
the US, Italy, and the UK, and will monitor long-
term efficacy, safety, and tolerability.
1.2.1 Bladder Cancer
In June 2009, Pfizer initiated an open-label
phase I trial (NCT00880854) of tremelimumab
in combination with Bacillus Calmette-Gue´rin
(BCG) in patients with BCG-resistant, recurrent
bladder cancer. This study will investigate the
safety, efficacy, and immunogenicity of the ther-
apy in approximately 24 patients in the US.
1.2.2 Breast Cancer
According to the September 2008 Pfizer pipe-
line, a phase I trial was initiated in this indication.
However, as of June 2010, no development has
been reported.
1.2.3 Colorectal Cancer
Pfizer has completed a phase II trial
(NCT00313794) evaluating tremelimumab as a
monotherapy in 49 patients with refractory
metastatic adenocarcinoma of the colon or rec-
tum who failed standard chemotherapy. The
single-arm study was conducted at sites in the US
and Canada. Patients received 15mg/kg every
90 days via intravenous infusion until disease
progression. The primary objective was response
rate by RECIST (Response Evaluation Criteria
In Solid Tumours) criteria. Secondary objectives
included safety, duration of response, progression-
free survival, and overall survival. A single pa-
tient, who had a stable ovarian mass and a
substantial regression in an adrenal mass, re-
ceived a second dose. The remaining 46 patients
had disease progression or disease-related death
before reaching the planned second dose at
3 months.[3] Following the completion of this trial
in July 2008, no further development was re-
ported and as the indication does not appear on
the January 2010 Pfizer pipeline, development is
presumed to have been discontinued.
1.2.4 Gastrointestinal Cancer
According to Pfizer’s pipeline dated March
2009, tremelimumab is in phase II clinical devel-
opment for gastrointestinal cancers.
1.2.5 Liver Cancer
In December 2008, Pfizer initiated a phase II
trial (NCT01008358) of tremelimumab in pa-
tients with late-stage unresectable liver cancer
who also have hepatitis C infections. This pri-
mary endpoint of this single-armed study is the
tumor response following therapy. The study will
also evaluate changes in hepatitis C viral load.
Approximately 20 patients will be enrolled in
Spain.
1.2.6 Malignant Melanoma
Based on a co-development agreement with
Pfizer, Debiopharm Group began planning a
phase III trial of tremelimumab for the treatment
of unresectable late-stage malignant melanoma
using a biomarker to select individuals that
might respond to the therapy.[1] According to the
Debiopharm pipeline (accessed in June 2010),
phase III development has begun.
A phase III trial of tremelimumab in combi-
nation with either dacarbazine or temozolomide
in treatment-naive patients with surgically in-
curable metastatic melanoma was discontinued
by Pfizer due to interim results not demonstrating
superiority over standard chemotherapy. Overall
survival was the primary endpoint. Debiopharm
has used data from this trial to identify a bio-
marker within the responding population, which
is being used to select patients for their phase III
trial.[4-6]
Pfizer, in collaboration with the University
of Pittsburgh, is conducting a phase II trial
(NCT00610857) of tremelimumab in combination
with high-dose interferon-a-2b in patients with
recurrent inoperable stage III or IV melanoma.
This open-label study has completed enrollment
of 37 patients in the US. Promising interim re-
sults were reported at the 44th Annual Meeting
of the American Society of Clinical Oncology
(ASCO-2008).[7]
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A phase II study (NCT00254579) of trem-
elimumab (15mg/kg every 90 days) in 215 patients
with advanced refractory and/or relapsed mela-
noma is ongoing in the US, Argentina, Australia,
Canada, France, Germany, Italy, Spain, and the
UK. Objective response rate is the primary end-
point and enrollment was completed in June 2009.
Pfizer is conducting a phase II trial
(NCT00471887) of tremelimumab in patients
with late-stage or metastatic melanoma to inves-
tigate its mechanism of action. This open-label
study has reached its target enrollment of 34
patients and is being carried out in the US.
In August 2003, Pfizer initiated a phase I/II
study (NCT00086489) evaluating the efficacy
and safety of 2 dose levels (10 and 15mg/kg) of
tremelimumab in 125 patients with advanced
melanoma in the US. The endpoints are assessed
every 2–3 months up to 2 years from the first dose
of tremelimumab. Recruitment was completed in
October 2007.
A phase I/II trial of tremelimumab has been
conducted in the US in patients with advanced
melanoma. It was an open-label, non-randomized,
dose-escalation study sponsored by the M.D.
Anderson Cancer Center. Results have been
reported.[8]
1.2.7 Non-Small Cell Lung Cancer (NSCLC)
In June 2010, Pfizer completed a phase II study
(NCT00312975) involving 87 patients with late-
stage NSCLC who had stable disease following
first-line platinum based therapy. This random-
ized, open-label trial was conducted to assess the
efficacy of tremelimumab compared with best
supportive care and was conducted at sites across
the US, Canada, the UK, Czech Republic, and
South Korea. Interim results were presented at
ASCO-2009.[9]
1.2.8 Pancreatic Cancer
An open-label phase I trial (NCT00556023) is
underway in Canada and Italy to determine the
dose-limiting toxicities of tremelimumab in
combination with gemcitabine in approximately
48 patients with chemotherapy-naive, inoperable,
metastatic pancreatic cancer.
1.2.9 Prostate Cancer
A phase II, open-label, randomized study
(NCT00075192) of tremelimumab in 30 patients
with high-risk prostate cancer has was completed
in the US in June 2006. The trial compared the
efficacy of tremelimumab in combination with
neoadjuvant androgen ablation, with androgen
ablation alone.
A phase I, dose-escalation trial (NCT00702923)
is underway in the US to determine the safety of
tremelimumab in combination with bicalutamide
(a short-term androgen deprivation drug) in approx-
imately 24 patients with prostate-specific antigen-
recurrent non-metastatic (stageD0) prostate cancer.
1.2.10 Renal Cancer
A phase I trial (NCT00372853) is underway
to determine the highest tolerable dose of
tremelimumab when given in combination with
sunitinib in patients with previously untreated
metastatic renal cell carcinoma. Enrollment of
28 patients was completed in January 2010.
1.2.11 Urogenital Cancer
According to Pfizer’s pipeline dated March
2009, tremelimumab is in phase II development
for urogenital cancer.
2. Scientific Summary
2.1 Pharmacokinetics
A phase I study evaluated the pharmacokine-
tics and clinical activity of tremelimumab in 39
patients with advanced solid malignancies. As per
ELISA results, peak plasma concentrations and
systemic exposure of tremelimumab were dose
dependent. After doses of ‡6mg/kg, the plasma
concentrations of tremelimumab were >10 mg/mL
(target efficacious concentration) and remained
at this level for >4 weeks. Tremelimumab had an
elimination half-life of 25.6 days.[10]
2.2 Adverse Events
2.2.1 Colorectal Cancer
Phase II: Tremelimumab (15mg/kg, intra-
venous infusion) was well tolerated without any
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unexpected and manageable adverse events in
patients with relapsed/refractory colorectal can-
cer despite standard chemotherapy in a phase II
study. Treatment-emergent grade 3/4 adverse events
were diarrhea (6.4%) and idiopathic thrombo-
cytopenia purpura (2.1%). The frequency of
grade 2 diarrhea was 8.5%.[3]
2.2.2 Malignant Melanoma
Phase III: The most common adverse events in
a phase III study in 655 patients with advanced
melanoma were diarrhea (43% overall, 14% grade
3/4), pruritis (25%), and rash (23%). Of the 655
patients, 328 were randomized to receive oral
tremelimumab 200mg/m2 on days 1–5 of a 28-day
cycle (324 treated) and 327 to intravenous da-
carbazine 1000mg/m2 every 21 days (319 treated).
Pituitary or adrenal gland toxicities were ob-
served in 3% of patients, and thyroid toxicities
in 4%. There were three treatment-related deaths
in the active arm, compared with none in the
control arm.[11]
Phase II: Intravenous tremelimumab (15mg/kg,
every 12 weeks) appeared to be well tolerated in
patients with advanced (incurable stage III or IV)
malignant melanoma in a phase II, open-label,
single-arm study (n = 251). The majority of
treatment-related adverse events were mild to
moderate. Grade 3 or 4 AEs included diarrhea
(n = 28, 11.4%), fatigue (n = 6, 2.4%), and colitis
(n = 6, 2.4%). There were two (0.8%) treatment-
related deaths (one sudden death and one diver-
ticular perforation).[12]
Interim results of a phase II trial showed
acceptable tolerability for the combination of
tremelimumab with high-dose interferon-a-2b in
a phase II trial in patients with stage IV melano-
ma. Sixteen such patients received intravenous
tremelimumab 15mg/kg per 12-week treatment
course. Concurrently, interferon-a-2b was ad-
ministered, beginning with an intravenous in-
duction regimen of 20MU/m2 for 5 days per week
for 4 weeks, followed by a subcutaneous main-
tenance regimen of 10MU/m2 three times per
week for 8 weeks per treatment course. Beginning
Table I. Features and properties
Alternate names CP 675206; CP-675; CP-675, 206; CP-675206; Ticilimumab
Originator Pfizer
Highest development phase III (US)
Active development-indications Bladder cancer, gastrointestinal cancer, liver cancer, malignant melanoma, non-small
cell lung cancer, pancreatic cancer, prostate cancer, renal cancer, urogenital cancer
Class Monoclonal antibodies
Mechanism of action Cytotoxic T-lymphocyte antigen 4 inhibitors, interleukin-2 stimulants
Chemical name Immunoglobulin G2, anti-(human cytotoxic T-lymphocyte protein 4 [CD 152 antigen]) [human
monoclonal CP-675206 clone 11.2.1 heavy chain] disulphide with human monoclonal CP-675206 clone
11.2.1 light chain, dimer
Molecular formula C6500 H9974 N1726 O2026 S52
CAS registry number 745013-59-6
Route of administration IV
Pharmacodynamics Enhances production of interleukin-2 in T cells of cancer patients
ATC codes
WHO ATC code L01X-C (monoclonal antibodies)
EphMRA ATC code L1X3 (antineoplastic monoclonal antibodies)
Pharmacokinetics
t½b (h): 614.4 (unspecified)
Adverse events
Occasional Colitis, dermatitis, diarrhea, fatigue, pruritus, skin eruptions, vitiligo
Rare Gastrointestinal perforations, idiopathic thrombocytopenic purpura, sudden death
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with the second treatment course, interferon-a-2b
was administered only subcutaneously as 10MU/m2
three times per week. The rate of adverse events
of grade 3/4 severity with the combination was
not more than that observed with high-dose
interferon-a-2b only. Grade 3/4 adverse events
included neutropenia (n = 3); elevations of hep-
atic enzymes to more than 5 times the upper limit
of normal (n = 2); fatigue (n = 6); and anxiety
(n = 2). Grade 4 autoimmune colitis was observed
in one patient and resulted in withdrawal from
the study; the patient subsequently recovered
completely.[7]
In a phase II study involving 28 patients with
advanced melanoma, two patients at the monthly
dose (10mg/kg) and five patients at the quarterly
dose (15mg/kg) continued on the study beyond
1 year. Currently, six patients at the monthly dose
and two patients at the quarterly dose have dis-
continued due to toxicity. There have been no
drug-related deaths in the study.[8]
Phase I: In a phase I study in melanoma
patients treated with tremelimumab, no grade
4 toxicities were observed. Grade 3 diarrhea oc-
curred in one patient at 3mg/kg and two patients
at 10mg/kg. Grade 2 treatment-related toxicities
included dermatitis (n = 4), and one case each
of diarrhea, pruritus, hypothyroidism, urticaria,
and myalgias. Toxicity in one patient who had
received ten doses at 10mg/kg, has been re-
stricted to autoimmune thyroiditis requiring hor-
monal replacement, de novo vitiligo, and chronic
pruritus.[13]
2.2.3 NSCLC
According to interim results from a phase II
trial (NCT00312975; n= 87), the incidence of
treatment-emergent adverse events was 61% and
7% following first-line maintenance therapy with
tremelimumab plus best supportive care (BSC)
and BSC alone in patients with advanced
NSCLC. Grade 3/4 adverse events were reported
in 21% and 0% of patients receiving trem-
elimumab plus BSC and BSC alone, respectively.
The most frequently reported tremelimumab-
related grade 3/4 adverse events were diarrhea
and colitis.[9]
2.2.4 Solid Tumors
Phase I: In a phase I study in 39 patients with
advanced solid malignancies, tremelimumab was
safe and well tolerated. The most frequently re-
ported adverse events included dermatitis (39%),
fatigue (39%), pruritus (25%), and diarrhea (25%).
Dose-limiting toxicities were grade 3 diarrhea
at 6mg/kg (n = 1) and 15mg/kg (3), and grade
3 dermatitis at 15mg/kg (1). The single MTDwas
10mg/kg. All autoimmune adverse events except
vitiligo were manageable and reversible.[10]
2.3 Pharmacodynamics
2.3.1 Cancer
Preclinical Studies
Tremelimumab showed affinities of 0.28 and
0.98 nmol/L for binding to human and monkey
CTLA4 immunoglobulin, respectively. The anti-
body was >500-fold more selective for human
CTLA4 immunoglobulin than for human CD28
immunoglobulin, B7.2 immunoglobulin, or IgG1.
Tremelimumab inhibited binding of human
CTLA4 immunoglobulin to immobilized B7.1
and B7.2 with respective concentrations that in-
hibit 50% (IC50) values of 0.65 and 0.50 nmol/L.
In human T-cell blasts stimulated with B7-
positive Raji cells, tremelimumab enhanced pro-
duction of IL-2 and interferon-g.
In human and cynomolgus monkey whole
blood and peripheral blood mononuclear cells
stimulated with staphylococcal enterotoxin A
superantigen, tremelimumab dose-dependently
enhanced IL-2 production.[14]
In vitro, whole blood and peripheral blood
mononuclear cells from both normal donors and
patients with cancer at different stages were
stimulated with staphylococcal enterotoxin A
superantigen and incubated with tremelimumab
(0.1–100 mg/mL) or an isotype-matched control
monoclonal antibody, for 72 hours at 37C.
Tremelimumab 30 mg/mL enhanced production
of IL-2 in both normal samples and those from
cancer patients, irrespective of tumor stage. Solu-
ble CTLA4 levels were <9 ng/mL in both normal
and cancer patient samples; staphylococcal en-
tertoxin A superantigen stimulation did not sig-
nificantly affect levels of CTLA4 expression.[15]
Tremelimumab 127
ª 2010 Adis Data Information BV. All rights reserved. Drugs R D 2010; 10 (2)
Table II. History
Date Comment
2 July 2010 inThought analysis for breast cancer updated
2 July 2010 inThought analysis for non-small cell lung cancer updated
30 June 2010 inThought analysis for colorectal cancer updated
28 June 2010 Debiopharm initiates enrollment in a phase III trial for unresectable metastatic malignant melanoma in the US before
June 2010
28 June 2010 No development reported – phase I for breast cancer in the US (IV)
14 June 2010 Pfizer completes a phase II trial (NCT00312975) in late-stage non-small cell lung cancer (in treatment experienced
patients) in the US, Canada, Czech Republic, South Korea, and the UK
19 April 2010 Phase II clinical trial (NCT00312975) in non-small cell lung cancer is ongoing but no longer recruiting patients
16 April 2010 inThought analysis for malignant melanoma updated
8 April 2010 Suspended – phase II for late-stage non-small cell lung cancer (in treatment experienced patients) in Canada (IV)
8 April 2010 Suspended – phase II for late-stage non-small cell lung cancer (in treatment experienced patients) in Czech
Republic (IV)
8 April 2010 Suspended – phase II for late-stage non-small cell lung cancer (in treatment experienced patients)
in South Korea (IV)
8 April 2010 Suspended – phase II for late-stage non-small cell lung cancer (in treatment experienced patients) in the UK (IV)
19 March 2010 Suspended – phase II for late-stage non-small cell lung cancer (in treatment experienced patients) in the US (IV)
19 February 2010 Pfizer completes enrolment in its Phase-II trial (NCT00312975) for non-small cell lung cancer in USA, Canada, the
UK, Czech Republic, and South Korea
19 January 2010 Pfizer completes enrollment in its phase I trial (NCT00372853) for metastatic renal cancer (in combination with
sunitinib) in the US
8 January 2010 Pfizer enters into a co-development agreement with Debiopharm for phase III development of tremelimumab in
patients with advanced malignant melanoma[1]
31 December 2009 Development discontinued for refractory metastatic colorectal cancer (second-line monotherapy in treatment
experienced patients) in the US and Canada after 2008
16 November 2009 Pfizer completes enrollment in its phase II trial (NCT00610857) for late-stage inoperable recurrent malignant
melanoma (in combination with high-dose interferon-a-2b) in the US
30 June 2009 Phase I clinical trials in BCG resistant, recurrent bladder cancer (in combination with BCG) in the US (IV)
13 June 2009 Pfizer completes enrollment in its phase II trial (NCT00254579) for late-stage refractory and/or relapsed melanoma
in the US, Argentina, Australia, Canada, France, Germany, Italy, Spain, and the UK
2 June 2009 Interim efficacy and adverse events data from a phase II trial in non-small cell lung cancer were presented at the 45th
Annual Meeting of the American Society of Clinical Oncology (ASCO-2009)[9]
7 May 2009 Pfizer completes enrollment in its phase II trial (NCT00471887) for late-stage or metastatic malignant melanoma in
the US
31 March 2009 Phase II clinical trials in gastrointestinal cancer in the US (IV)
31 March 2009 Phase II clinical trials in urogenital cancer in the US (IV)
1 December 2008 Phase II clinical trials in late-stage unresectable liver cancer in Spain (IV)
30 September 2008 Phase I clinical trials in breast cancer in the US (IV)
16 September 2008 Safety and efficacy data from a phase II trial in patients with advanced malignant melanoma presented at the 33rd
Congress of the European Society for Medical Oncology (ESMO-2008)[12]
31 July 2008 Phase I clinical trials of tremelimumab in combination with bicalutamide in prostate cancer in the US (IV)
14 July 2008 Pfizer completes a phase II trial (NCT00313794) in refractory metastatic colorectal cancer (second-line
monotherapy in treatment experienced patients) in the US and Canada
30 June 2008 Phase I clinical trials in inoperable, metastatic pancreatic cancer (in combination with gemcitabine in treatment-
naive patients) in Italy (IV)
30 June 2008 Phase I clinical trials in inoperable, metastatic pancreatic cancer (in combination with gemcitabine in treatment naive
patients) in Canada (IV)
Continued next page
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2.4 Therapeutic Trials
2.4.1 Cancer
Colorectal Cancer
Phase II: Tremelimumab (15mg/kg, intra-
venous infusion) did not demonstrate substantial
single-agent activity in patients with relapsed/
refractory, metastatic, colorectal cancer despite
standard chemotherapy in a phase II study (n= 47).
Only one patient had a stable ovarian mass and a
substantial regression in an adrenal mass; this
patient has progressed to the second dose. The
Table II. Contd
Date Comment
3 June 2008 Efficacy data from a phase I/II trial in malignant melanoma presented at the 44th Annual Meeting of the American
Society of Clinical Oncology (ASCO-2008)[16]
3 June 2008 Final efficacy data from a phase III trial in malignant melanoma presented at the 44th Annual Meeting of the
American Society of Clinical Oncology (ASCO-2008)[11]
3 June 2008 Interim efficacy data from a phase II trial of tremelimumab in combination with high-dose interferon-a-2b presented
at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)[7]
30 May 2008 Phase II clinical trials of tremelimumab in combination with interferon-a-2b in malignant melanoma in the US (IV)
2 April 2008 Discontinued – phase III for malignant melanoma in the world (IV)
7 February 2008 Phase II clinical trials in late-stage inoperable recurrent malignant melanoma (in combination with high-dose
interferon-a-2b) in the US (IV)
22 October 2007 Pfizer completes enrollment in its phase I/II trial (NCT00086489) for late-stage melanoma in the US
19 June 2007 Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2007) added to the
adverse events and cancer therapeutic trials sections[3,8]
31 December 2006 Phase I clinical trials in metastatic renal cancer (in combination with sunitinib) in the US (IV)
8 June 2006 Pfizer completes a phase II trial (NCT00075192) for prostate cancer (in combination with neoadjuvant androgen
ablation therapy) in the US
31 May 2006 Phase II clinical trials in late-stage non-small cell lung cancer (in treatment-experienced patients) in Canada (IV)
31 May 2006 Phase II clinical trials in late-stage non-small cell lung cancer (in treatment-experienced patients) in South Korea (IV)
31 May 2006 Phase II clinical trials in late-stage non-small cell lung cancer (in treatment-experienced patients) in the UK (IV)
31 May 2006 Phase II clinical trials in late-stage non-small cell lung cancer (in treatment-experienced patients) in the US (IV)
31 May 2006 Phase II clinical trials in late-stage non-small cell lung cancer (in treatment experienced patients) in the Czech
Republic (IV)
31 May 2006 Phase II clinical trials in refractory metastatic Colorectal cancer (second-line monotherapy in treatment experienced
patients) in USA (IV)
31 May 2006 Phase II clinical trials in refractory metastatic colorectal cancer (second-line monotherapy in treatment experienced
patients) in Canada (IV)
31 December 2005 Phase II clinical trials in late-stage refractory and/or relapsed malignant melanoma in Argentina (IV)
31 December 2005 Phase II clinical trials in late-stage refractory and/or relapsed malignant melanoma in Canada (IV)
31 December 2005 Phase II clinical trials in late-stage refractory and/or relapsed malignant melanoma in the EU (IV)
31 December 2005 Phase II clinical trials in late-stage refractory and/or relapsed malignant melanoma in the US (IV)
31 December 2005 Phase II clinical trials in late-stage refractory and/or relapsed malignant melanoma in Australia (IV)
30 December 2005 Phase III clinical trials in malignant melanoma in the US (IV)
18 May 2005 Data presented at the 41st Annual Meeting of the American Society of Clinical Oncology have been added to the
adverse events and cancer therapeutic trials sections[13]
6 July 2004 Data presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2004) have been
added to the adverse events, pharmacokinetics and cancer therapeutic trials sections[10]
20 April 2004 Phase I/II clinical trials in malignant melanoma in the US (IV)
20 April 2004 Phase II clinical trials in prostate cancer in the US (IV)
20 April 2004 Profile created from data presented at the 95th Annual Meeting of the American Association for Cancer Research
(AACR-2004)
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other 46 patients experienced disease progression
or disease-related death before reaching the planned
second dose at 3 months.[3]
Malignant Melanoma
Phase III: Tremelimumab as a single-agent,
first-line therapy failed to demonstrate an im-
provement in overall survival compared with
chemotherapy in a phase III study in 655 patients
with advanced melanoma. Of the 655 patients,
328 were randomized to receive oral trem-
elimumab 200mg/m2 on days 1–5 of a 28-day
cycle (324 treated) and 327 to intravenous da-
carbazine 1000mg/m2 every 21 days (319 treat-
ed). The primary endpoint of improved overall
survival was not met; it was 11.8 months and 10.7
months in the tremelimumab and dacarbazine
groups, respectively. Based on a protocol speci-
fied second interim analysis with 340 deaths, the
independent DSMC (Direct Simulation Monte
Carlo) advised to stop the study as the log-rank
test statistic crossed the O’Brien-Flemming futil-
ity boundary.[11]
Phase II: Patients with advanced (incurable
stage III or IV)malignantmelanoma in a phase II,
open-label, single-arm study (n = 251) experi-
enced potentially beneficial tumor responses
when treated with tremelimumab (15mg/kg, in-
travenous infusion every 12 weeks). Among
242-response evaluable participants, there were
11 cases of ongoing partial responses, which
ranged from 6.0+ to 17.7+ months. The majority
of partial responses involved target lesions in
lung, lymph nodes, and/or liver. An additional
36 patients had stable disease; thus, the clinical
benefit rate was 22% (partial responses plus stable
diseases). Six patients (2.5%) had a partial res-
ponse in target lesions while having overall pro-
gressive disease, and these patients remain alive
on study with censored overall survival, which
ranged from 14.82+ to 18.23+ months. Median
overall survival for all patients was 10.1 months,
and Kaplan-Meier estimate of 12-month survival
was 41%. While the findings did not show a second-
line response rate exceeding 10%, the duration
of response to this regimen indicated that trem-
elimumab could be beneficial in this population.[12]
Interim results of a phase II trial showed
promising efficacy for the combination of
tremelimumab with high-dose interferon-a-2b in
a phase II trial in patients with stage IV melano-
ma. Sixteen such patients received intravenous
tremelimumab 15mg/kg per 12-week treatment
course. Concurrently, interferon-a-2b was ad-
ministered, beginning with an intravenous in-
duction regimen of 20MU/m2 for 5 days per week
for 4 weeks, followed by a subcutaneous main-
tenance regimen of 10MU/m2 three times per week
Table III. Forecasts
InThought Probability of Approvala
Indication Approval Date Estimate inThought Approvability Index Last Update
Gastrointestinal cancer NE 31% (NYR) 27 Jul 2009
Malignant melanoma NE 63% (NYR) 16 Apr 2010
Non-small cell lung cancer NE 31% (NYR) 2 Jul 2010
Pancreatic cancer NE 25% (NYR) 27 Jul 2009
Prostate cancer NE 31% (NYR) 27 Jul 2009
Renal cancer NE 25% (NYR) 27 Jul 2009
a The Wolters Kluwer Health Approvability Index is a dynamic tool that assesses the progress of a drug candidate through clinical
development, evaluating strength of clinical data and trial design, benchmarked against historical parameters and likelihood to maintain
forward momentum. Points are assigned for specific line items relating to safety, efficacy, and other factors in each phase of clinical
development. Possible points total 100 upon drug approval, and are allocated in each phase according to the historical approval rate of
similar drugs, such that the current points of a drug relate to its probability of approval. In addition, a letter grade is assigned and reflects the
momentum of a drug candidate in its current phase, with ‘‘A’’ indicating significantly above average/likely to progress, ‘‘C’’ indicating
average, and ‘‘F’’ indicating significantly below average/unlikely to progress. ‘NYR’ stands for ‘Not Yet Rated,’ indicating that the probability
of approval is based on historical approval rates for similar drugs according to indication, molecule type, novelty, and phase, but without
analyses of clinical data, trial design, and other factors specific to the individual agent.
NE = no estimate; NYR = not yet rated.
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for 8 weeks per treatment course. Beginning with
the second treatment course, interferon-a-2b was
administered only subcutaneously as 10MU/m2
three times per week. There were partial re-
sponses in 3 of 16 (19%) patients after adminis-
tration of a total of 24 treatment courses (median
of one course per patient); these responses lasted
for ‡2 months. Six patients had stable disease
lasting £4.5 months and disease progression was
observed in three patients.[7]
In the phase II portion of a phase I/II
trial involving 28 patients with histologically
confirmed stage IIIc (unresectable) or stage IV
recurrent metastatic melanoma, tremelimumab
doses of 10mg/kgmonthly and 15mg/kg quarterly
showed a median overall survival rate of
10.3 months and 11.2 months, respectively. In
the phase I portion, an estimated 21.7-month
median overall survival rate was observed across
several dose groups of tremelimumab (3, 6, and
10mg/kg).[8]
Phase I/II: Data derived from a phase I/II,
randomized, open-label trial in 119 adult patients
with stage III/IV melanoma suggested that those
patients receiving previous therapy with IL-2
derived less benefit from tremelimumab than
patients not treated with IL-2. The researchers
noted that a number of confounding factors may,
however, have introduced bias into the data, and
further larger studies are planned.[16]
Phase I: In a phase I trial in 14 stage IIIc/IV
melanoma patients, one patient receiving trem-
elimumab at 10mg/kg had an ongoing response
at the time of reporting, and continues on therapy
after ten doses. Four biopsies of residual lesions
revealed no melanoma in most areas with a
dermo-epidermal CD3/CD8 lymphocytic infiltrate. An
area with viable melanoma cells had a prom-
inent intratumoral CD3/CD8 lymphocytic infiltrate.
Another patient receiving tremelimumab 10mg/kg
developed a new brain metastasis at 2 months.
After external radiation therapy, no new meta-
stases were noted for 7 months with stable lymph
node metastasis.[13]
NSCLC
According to interim results from a phase II
trial (NCT0031297; n = 87), first-line mainten-
ance tremelimumab plus BSC did not sig-
nificantly increase the progression-free survival
rate at 3 months (primary endpoint), compared
with best supportive care alone, in patients with
advanced non-small cell cancer (21% vs 14% of
patients). The partial response rate was 5% in the
tremelimumab plus BSC group and 0% in the
BSC group; the stable disease rate was 17.5% and
14% in the respective groups.[9]
Solid Tumors
Phase I: There were two complete responders
(18+, 8+ months), one partial responder and six
cases of stable disease (3+ to 16 months) among
34 patients with measurable disease in a phase I
trials (n = 39). Patients were administered a single
intravenous infusion of tremelimumab at seven
dose levels (0.01, 0.1, 1.0, 3.0, 6.0, 10.0, and
15mg/kg). Five patients in the lowest dose cohort
were also re-enrolled and received treatment at a
higher dose level.[10]
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